跳至主要内容
临床试验/JPRN-UMIN000001221
JPRN-UMIN000001221已完成2 期

A Phase II trial of combination therapy of gemcitabine and hyperthermia in unresectable pancreatic cancer. - Combination therapy of gemcitabine and hyperthermia in unresectable pancreatic cancer.

Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine0 个研究点目标入组 18 人开始时间: 2008年7月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • Exclusion criteria in this study are as follows: 1. Interstitial pneumonitis, pulmonary fibrosis with radiological findings 2. Recurrence after resection for CBD cancer or presence of hepatocellular carcinoma, duodenal cancer, peritonitis carcinomatosa. 3. Presence of ileus 4. Presence of active biliary infection 5. Presence of uncontrolled diabetes, severe liver dysfunction, unstable angina, myocardial infarction within three months. 6. Presence of active severe infection 7. Pregnant, lactating women or women with suspected pregnancy. 8. Medical history of severe hypersensitivity. 9. Severe complications 10. Inappropriate patients for this study judged by the physicians.

研究者

发起方
Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

相似试验